

Circulating Tumor Cell Subtypes may Predict Responses to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Ge Ma

The First Affiliated hospital with Nanjing Medical University

Jingyi Wang

The First Affiliated Hospital with Nanjing Medical University

Xingmeng Wang

The First Affiliated Hospital with Nanjing Medical University

Hanling Zeng

The First Affiliated Hospital with Nanjing Medical University

Minghui Li

The First Affiliated Hospital with Nanjing Medical University

Xu Han

The First Affiliated Hospital with Nanjing Medical University

Xinrui Mao

The First Affiliated Hospital with Nanjing Medical University

Yi Jiang

The First Affiliated Hospital with Nanjing Medical University

Tiansong Xia

The First Affiliated Hospital with Nanjing Medical University

Xiaoan Liu

The First Affiliated Hospital with Nanjing Medical University

shui wang (✉ ws0801@hotmail.com)

The First Affiliated Hospital with Nanjing Medical University <https://orcid.org/0000-0001-8878-9162>

Research article

Keywords: Neoplastic cells, circulating; breast neoplasms; neoadjuvant therapy; biomarkers

Posted Date: February 14th, 2020

DOI: <https://doi.org/10.21203/rs.2.23526/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Neoadjuvant chemotherapy (NCT) is the standard treatment for patients with locally advanced breast cancer (LABC). However, the predictive value of circulating tumor cells (CTCs) with different molecular subtypes in NCT response has not yet been determined, which was, therefore, the aim of this study. **Methods:** All patients were staged as LABC and received an EC×4 – T×4 NCT regimen. Blood samples were collected from patients at the time of biopsy, and after the first and eighth NCT courses. Patients were divided into High responders (High-R) and Low responders (Low-R) according to Miller-Payne system and changes in Ki-67 levels after NCT treatment. A novel SE-i•FISH strategy was applied to detect CTCs. Subtypes were successfully analyzed in LABC patients undergoing NCT, for the first time. **Results:** Total CTCs increased continuously and were higher for Low-R patients; while in the High-R group, total CTCs increased slightly during NCT before returning to baseline levels. Triploid and tetraploid chromosome 8 as well as the proportion of each, increased for Low-R but not High-R patients. The number of small CTCs in the Low-R group increased significantly until the last sample, however, remained constant in the High-R group. The patients with more CTCs had shorter PFS and OS than those with less CTCs after the 8th course of NCT. **Conclusions:** Total CTCs as well as individual subtypes within peripheral blood following NCT were predictive of patient responses to NCT. More detailed characterization of CTC blood profiles may improve predictive capacity and lead to improved LABC treatments.

Background

Breast cancer is the most common malignant tumor in women, and neoadjuvant chemotherapy (NCT) is the standard of care for patients with locally advanced breast cancer (LABC)[1]. However, a large number of patients with breast cancer respond poorly to standard treatment, and only a small number of patients achieve a complete or optimal response. In addition, chemotherapy can induce a significant, unexpected "opposite effect" that accelerates critical metastatic steps in malignancy, rather than inhibiting them[2]. Tumor heterogeneity may account for the differing therapeutic effects and should be appropriately addressed in treatment response evaluation. NCT should achieve two main objectives: shrinkage of the primary tumor and eradication of blood-borne tumor cell dissemination[3]. However, in practice due to the lack of standard testing criteria, the second objective is almost entirely overlooked by current NCT assessments despite metastasis being the primary cause of death in breast cancer patients[4].

Circulating tumor cells (CTCs) are released from the primary tumor into the blood stream and are considered to be the initiators of metastasis at distant organ sites[5]. In early breast cancer, CTC detection rates are 8–56%, according to different methods[6–8]. Numerous studies have demonstrated that the presence of CTCs in early breast cancer is a marker of poor prognosis[9, 10]. In the case of LABC, The German Breast Group demonstrated that detection of CTCs prior to NCT is an independent prognostic factor of impaired clinical outcome, and is particularly effective when combined with pCR[11]. Although sufficient evidence exists to recognize the prognostic value of CTCs as an example of high-quality evidence-based medicine, complete elucidation of the quantitative changes and molecular characterization of CTCs during NCT have not been carried out, which may serve to improve the unfavorable prognoses of CTC patients.

CTCs are present at very low concentrations in peripheral blood, and therefore, highly sensitive assays are required. Conventional detection strategies include two steps, enrichment and detection (or characterization). The Cell Search System is unable to effectively detect multi-functional mesenchymal CTCs while real-time PCR (RT-PCR)-based tumor cell detection methods cannot accurately measure CTC numbers by gene expression measurement[12]. Recently, a novel CTC detection strategy, subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-i•FISH) has been applied. This technique integrates both steps and achieves much higher sensitivity; negative selection, which does not limit CTC isolation to those expressing particular tumor markers, is used to enrich CTCs using the leukocyte marker CD45[13]. This system is an innovative means to detect chromosome aneuploidy with synchronous detection of the tumor biomarkers listed above. Aneuploidy may result in genomic instability[14]. In fact, several studies have described it as the most common feature of malignant tumor cells[15, 16]. Further, using SE-i•FISH enables observation of CTC morphological features. For instance, small CTCs (< 5 µm) as well as circulating tumor microemboli (CTM; a cluster of two or more CTCs) can be distinguished from CTCs in the traditional sense. In summary, the benefits of SE-i•FISH include not only improved enumeration of CTCs, but also more detailed characterization and analytical opportunities that may be investigated during NCT assessments.

The aim of this study was to evaluate the predictive power of different CTC subtypes with respect to LABC patients receiving NCT. Further, we explore the future prospects for liquid biopsy and characterization of CTC heterogeneity in NCT.

Materials And Methods

Patients and sample collection

Written, informed consent was obtained from all patients prior to enrolment in the study. All procedures were approved by Institutional Review Boards of the First Affiliated Hospital with Nanjing Medical University.

A total of 45 patients diagnosed with LABC were enrolled at the First Affiliated Hospital of Nanjing Medical University from October 2016 to November 2017. Breast cancer in all patients was confirmed by core biopsy. The pathological report, including histological type, hormone receptors, HER-2 status, and Ki-67 index were provided by the Pathology Department of the First Affiliated Hospital of Nanjing Medical University. All patients were staged as LABC and received an EC×4–T×4 NCT regimen (epirubicin 90 mg/m² iv d1, cyclophosphamide 600 mg/m² iv d1 on a 21 days cycle for four cycles, then docetaxel 80 mg/m² iv d1, on a 21 days cycle for four cycles). Blood samples (6 mL) were collected for CTC detection pre-treatment (at time of biopsy) and after the first and eighth courses of chemotherapy. Complete blood counts (lymphocyte, neutrophils and platelets) referred to the blood cell analysis reported by Clinical Laboratory of the First Affiliated Hospital of Nanjing Medical University. All patients with breast cancer underwent surgery. The Ki-67 values from the postoperative and preoperative biopsy pathology reports were compared and used to evaluate the NCT response. All patients were assigned to one of two groups, those in the

Low-Responder (Low-R) group had a higher Ki-67 index following NCT, compared to the 66.67% basal Ki-67 value prior to NCT; alternatively, the High-Responder (High-R) group had a lower Ki-67 index. Additionally, the Miller-Payne system was applied for NCT response classification[17].

Immunofluorescence staining and SE-iFISH

In this study, we applied the subtraction enrichment (SE) and immunostaining-FISH, iFISH[®] platform for CTC detection and characterization[18, 19]. Experiments were performed according to the operation manual (Cytelligen, San Diego, CA, USA). Briefly, peripheral blood and cerebrospinal fluid were collected into Cytelligen tubes containing ACD anti-coagulant (Becton Dickinson, Franklin Lakes, NJ, USA) and centrifuged at $450 \times g$ for 5 min. All sedimented cells were subsequently loaded onto the top of 3 mL non-hematopoietic cell separation matrix for immediate processing by density gradient centrifugation.

Supernatants above the red blood cell layer were collected and incubated with a cocktail including anti-leukocyte antibody (CD45) immunomagnetic beads at 23-25 °C for 15 min with gentle shaking. Subsequently, the solution was subjected to magnetic separation. The bead free solution was spun at $500 \times g$ for 2 min. Sedimented cells were thoroughly mixed with cell fixative and applied to coated CTC slides for subsequent iFISH analysis.

Air-dried samples on coated CTC slides were hybridized with centromere probe 8 (CEP8) (Abbott Laboratories, Abbott Park, IL, USA) for 3 h, followed by antibody staining by incubation with Alexa Fluor (AF) 594-anti-CD45, Cy5-anti-EpCAM (epithelial cell adhesion marker), Cy7-anti-vimentin, and AF488-anti-CD31 at room temperature for 30 min.

Metafer- iFISH[®] automated CTC 3D scanning and image analysis

Image capture, as well as CTC identification and analysis were performed using the automated Metafer- iFISH[®] CTC 3D scanning and analyzing system (Carl Zeiss, Oberkochen, Germany; MetaSystems, Altlussheim, Germany; and Cytelligen, San Diego, CA, USA). Briefly, CTC slides loaded onto a fluorescence microscope (AXIO Imager Z2) stage were subjected to automated full X-Y plane scanning with cross Z-sectioning of all cells performed at a 1 mm step depth, with fluorescence signal acquisition of all color channels. Automated image processing, classification, and statistical analysis were performed to comprehensively evaluate cell size, cell cluster, tumor biomarker expression, and chromosome ploidy. A cell was judged to be CTC if it matched either of the following criteria:

- (1) DAPI⁺CD45⁺CD31⁺EpCAM[±]/vimentin[±]/chromosome 8 (Chr8) aneuploidy or polyploidy
- (2) DAPI⁺CD45⁺CD31⁺chr8 diploidy/minimum one tumor biomarker(s)⁺

Statistical analysis

Results are expressed as the mean \pm SD. The number of CTCs and different subtypes were analyzed by repetitive measurement deviation analysis between the High-R and Low-R groups. Multiple comparison analysis corrected by Tukey's test was used to analyze the differences within groups. Chi-square analysis was used to determine the CTC positive rates in patients with different clinicopathological features. To evaluate the predictive value of CTC occurrence in distinguishing chemotherapy-resistant patients from sensitive ones, we plotted receiver operating characteristic (ROC) curves and calculated the area under the curves (AUCs). The ROC curves of total and subtype CTC numbers were generated at three time points. The Δ value, defined as the difference between the two measurements, was also analyzed by ROC curve. Correlation coefficients of two variables were calculated with Pearson analysis. Survival analysis was performed using Log-rank test. All statistical analyses were performed with SPSS version 21.0 (SPSS, IBM; Chicago, IL, USA), and all p values were two-tailed with 5% significance levels.

Results

Establishment of SE-iFISH for breast cancer CTCs in situ phenotype and karyotype identification

SE-iFISH was optimized to monitor breast cancer CTCs expressing tumor biomarkers and Chr8 aneuploidy. Immunofluorescence staining of CTCs and CECs with anti-EpCAM and mesenchymal marker vimentin showed distinct intracellular staining for both EpCAM and vimentin. (Fig. 1).

Analysis of CTCs detected by patient classification

The CTC positive detection rate was 43/45 in LABC patients (95.6%) before NCT, and 100% following the first course of NCT and post-NCT.

Patients were divided into two groups according to changes in Ki-67. The High-R group was comprised of 22 patients (48.9%) and the Low-R group of 23 patients (51.1%). According to the Miller-Payne system, 8/45 patients obtained >90% loss of tumor cells (grade 4–5), while the other 37 patients were assigned to grade 1–3. All eight grade 4–5 patients belonged to the High-R group when sorted according to Ki-67 changes.

Patient clinicopathological features and their association with CTC detection are shown in Table 1. The CTC positive rate was not correlated with age, HER-2 status, or lymph node metastasis. However, patients with more than two lymph node metastases exhibited significantly higher numbers of CTCs (repetitive measurement deviation analysis, $p = 0.029$). Further, during NCT, CTC numbers increased in patients with more than two metastatic lymph nodes ($p < 0.001$ and 0.043 for post-1st NCT and post-NCT, respectively, additional file 1, Figure S1A). Specifically, the CTC number was high only during NCT in the High-R group, yet was continuously elevated in the Low-R group. Alternatively, for patients with two or less metastatic lymph nodes, the CTC number showed a downward trend following the initial rise in the High-R group; while in the Low-R group the number was found to steadily increase (Additional file 1, Figure S1A and 1B).

Table 1
CTC numbers of patients with different clinical characteristics

Factors	Total (No.)	High-R (No.)	Low-R (No.)	CTC number					
				p value	pre-NCT	post-1st NCT	post-NCT	p value ¹	p value ²
Total	45	22	23						
Age				0.181				< 0.001	0.545
< 50	22	13	9		8.18 ± 7.82	111.18 ± 160.25	32.55 ± 45.48		
≥ 50	23	9	14		6.44 ± 5.53	49.78 ± 63.22	66.91 ± 93.04		
Her-2 status				0.848				0.001	0.111
Negative	28	14	14		6.72 ± 6.18	70.14 ± 130.58	40.28 ± 61.69		
Positive	17	8	9		8.31 ± 7.73	97.31 ± 110.92	67.94 ± 94.06		
Molecular subtype				0.815				0.002	0.117
Hormone + Her-2-/+	33	17	16		7.30 ± 6.82	58.49 ± 76.48	47.12 ± 77.27		
TNBC	10	4	6		7.25 ± 6.74	138.42 ± 196.83	58.33 ± 70.71		
Hormone-Her-2+	2	1	1		8.50 ± 3.54	140.00 ± 195.16	124.00 ± 4.24		
Lymph node				0.100				< 0.001	0.029
≤ 2	23	14	9		6.63 ± 6.77	48.92 ± 52.36	34.83 ± 57.57		
> 2	22	8	14		8.05 ± 6.76	115.81 ± 166.65	67.57 ± 89.14		
P value1: different timepoints									
P value2: clinical characteristics									

CTC numbers analyzed by patient group: correlation with NCT effect

A typical fluorescent photograph of a CTC is shown in Fig. 2A. Generally, the number of CTCs increased after the first NCT cycle compared to pre-NCT levels ($p < 0.001$). This trend continued post-NCT ($p = 0.001$, Fig. 2B). The number of CTCs was higher in the Low-R group (repetitive measurement deviation analysis, $p = 0.042$). There were no significant differences in CTC number between High-R and Low-R groups before NCT or after the first course of NCT (Fig. 2C). However, following the eighth NCT course, the difference between the two groups was significant ($p = 0.028$). The CTC number increased slightly ($p = 0.051$), then decreased to baseline in the High-R group, while in the Low-R group, the number of CTCs continuously increased continuously during NCT (Fig. 2D).

According to the Miller-Payne system, the CTC number of grade 1–3 patients increased significantly and continuously following all NCT courses compared to grade 4–5 patients (Fig. 2E and 2F).

Chromosome 8 karyotype changes between patients with different NCT responses

The existence of heterogeneous polysomic Chr8 confirmed the marked heterogeneity of breast cancer CTCs (Fig. 3A); while the ratios of CTCs with different Chr8 ploidy levels changed during treatment (Fig. 3B). The frequencies of CTCs with triploid Chr8 copy numbers were 28, 34, and 45% at the three successive time points, and the corresponding tetraploid Chr8 numbers were 14, 27, and 24%, respectively. Analysis of the occurrence of triploid, tetraploid, pentaploid, or higher Chr8 copies in CTCs according to NCT response showed that the number of CTCs containing Chr8 triploidy and tetraploidy was higher in the Low-R group than in the High-R group following NCT, however, this effect was not observed pre- or post-initial NCT ($p = 0.017$ and 0.009 for triploidy and tetraploidy, respectively, Fig. 3C and 3G). Compared to the CTC number before NCT, an increase in Chr8 triploidy and tetraploidy was observed in the Low-R group post-first NCT ($p = 0.003$ and 0.010 , respectively) and post-NCT ($p = 0.002$ both in triploid and tetraploid Chr8); while in the High-R group, Chr8 triploidy only increased post-first NCT, after which it returned to baseline. No increase in tetraploid Chr8 was observed in CTCs following NCT in High-R group (Fig. 3D and 3H). Moreover, no significant differences were observed between the Low-R and High-R groups during NCT in the numbers of multiploid (\geq pentasomy 8) CTCs for either of the time points (Fig. 3K). Following NCT, the number and proportion of triploid and tetraploid CTCs rose continuously in only the Low-R group, not the High-R group.

In addition, no significant intragroup differences were observed in multiploid CTCs (Fig. 3L). When patients were classified by the Miller-Payne system, the trends observed in CTC Chr8 triploidy, tetraploidy and multiploid variations were similar to the ki-67 group mode (Fig. 3E-F, I-J, M-N).

Correlation of the number of small size CTCs with NCT response

A vimentin + small size CTC is depicted in Fig. 4A (left). The number of small CTCs ($< 5 \mu\text{m}$) increased after the first NCT cycle ($p < 0.001$), after which it remained elevated post-NCT ($p = 0.001$), consistent with the overall changes observed in CTCs (Fig. 4B). Further, the number of small CTCs in Low-R patients was significantly higher during the final time point after the eighth course of NCT ($p = 0.038$; Fig. 4C). This difference, however, reflected growth in the number of small CTCs after the first course ($p = 0.010$), which then plateaued at a comparatively high level ($p = 0.003$). Unlike the Low-R group, the CTC level of the High-R group remained approximately constant throughout the NCT process (Fig. 4D). The percentage of small CTCs in the High-R group were 30.5%, 30.4%, and 35.9%, respectively, at the three timepoints (Fig. 4G). The corresponding data for the Low-R group were 14.5%, 32.3%, and 46.7%. Additionally, the patients designated as Miller-Payne grade 1–3 exhibited the same trend in variation as that observed in the Low-R group, while grade 4–5 was observed to be the same as the High-R group (Fig. 4E-F).

CTM of LABC patients during NCT

A vimentin + CTM is depicted in Fig. 4A (right). No significant changes were observed in CTM numbers following the eighth course of NCT (repetitive measurement deviation analysis). However, the results in Low-R patients following the first course of treatment showed apparently higher numbers of CTM compared to those before NCT (Fig. 4I). No significant differences were observed between High-R and Low-R groups at the other timepoints; the CTM increase in the Low-R group only slightly exceeded the significance level ($p \leq 0.05$) at the second time point, post-first course ($p = 0.067$) (Fig. 4H).

CTC, mesenchymal phenotypes, and NCT sensitivity

Next, CTCs were grouped according to the presence or absence of the mesenchymal marker vimentin (Fig. 5A). The number of total and small vimentin⁻ CTCs increased during NCT. Further, the vimentin⁺ CTCs increased after the first NCT course, and decreased after the last course, whereas small vimentin⁺ CTCs increased after the first course, then remained approximately constant (Fig. 5B and 5C). Patients in the Low-R group displayed higher numbers of vimentin⁻ CTCs and small CTCs after NCT ($p = 0.060$ and 0.038 for CTCs and small CTCs, respectively, Fig. 5H and 5J). Conversely, no difference was found in vimentin⁺ CTCs, while an increased number of vimentin⁺ small CTCs was detected in the High-R group following the first course of NCT (Fig. 5D and 5F). Further, vimentin⁻ CTCs remained constant over the course of NCT treatment in the High-R group and increased in the Low-R group at which level it remained relatively constant until surgery ($p = 0.002$ and 0.008 for the first and eighth courses of NCT, respectively, Fig. 5I). In contrast, vimentin⁺ CTCs showed no significant changes during NCT (Fig. 5E). In terms of vimentin⁺ small CTCs, no significant changes in number were detected in the Low-R group during NCT. In contrast, vimentin⁺ small CTCs increased post-first NCT course after which they returned to baseline in the High-R group (Fig. 5G). Vimentin⁻ small CTCs showed no significant change in the High-R group, but in the Low-R group an obvious increase was observed after the first course of NCT, then levels remained high (Fig. 5K).

Cumulatively, these data indicate a possible correlation between low response to NCT and increased vimentin⁻ CTCs with no reduction in vimentin⁺ CTC numbers. The proportion of total vimentin⁻ CTCs confirmed this conclusion. In the Low-R group, the percentage of vimentin⁻ small CTCs rose from 10% before NCT to 46% after completion (Fig. 5L).

Correlation between CTCs and non-cancer cells (lymphocyte, neutrophils and platelets), CTCs and cancer biomarkers during NCT

The relationships between aneuploid CTCs and non-cancer cells (lymphocyte, neutrophils and platelets) were shown in Fig S2 (Additional file 2). The number of CTCs was positively correlated with neutrophils ($p = 0.005$, $r = 0.416$) and platelets ($p = 0.421$, $r = 0.004$) before treatment, however, these correlations were not apparent following the first course of NCT. Moreover, no correlation was observed between CTCs and the lymphocyte, tumor markers CEA, CA12-5, and CA15-3 (Additional files 2 and 3, Fig S2 and S3).

Predictive value of CTC numbers

ROC curve analyses indicated that the CTC total, as well as the individual subtypes, effectively predicted the NCT response after the eighth course of NCT. The AUCs for CTCs with different subtypes after the eighth course of NCT were 0.770 (95% confidence interval (CI) 0.630–0.909), 0.776 (95% CI 0.642–0.910), 0.777 (95% CI 0.640–0.913), 0.784 (95% CI 0.649–0.918), 0.772 (95% CI 0.632–0.911) and 0.792 (95% CI 0.663–0.922) for overall CTCs, small CTCs, trisomy 8 CTCs, tetrasomy 8 CTCs, vimentin⁻ CTCs, and vimentin⁻ small CTCs, respectively (all p values < 0.05 , Fig. 6A). Similarly, the $\Delta\text{value}2$ (difference between the third and the first measurements) was an effective predictor of outcome. The AUCs for this measurement were 0.797 (95% CI 0.670–0.925), 0.822 (95% CI 0.702–0.942), 0.776 (95% CI 0.641–0.910), 0.804 (95% CI 0.676–0.933), 0.794 (95% CI 0.666–0.923), and 0.845 (95% CI 0.732–0.958), respectively (all p values < 0.05 , Fig. 6B). Considering the samples after only the first course of treatment, only the $\Delta\text{value}1$ (difference between the second and the first measurements) of small vimentin⁻ CTCs exhibited significant diagnostic value (AUC 0.566; 95% CI 0.396–0.737; Fig. 6C). However, a lower degree of diagnostic efficiency was achieved when the Miller-Payne system was adopted, which may be related to the unbalanced sample size (Additional file 4, Fig S4).

A three-year follow-up of LABC patients was conducted to evaluate the curative effects of NCT and the rationality of the surrogate endpoints including Ki-67 changes. We set the media value of CTC numbers as a threshold, and divided subjects into a CTC-High and CTC-Low group. The comparison of progression-free survival (PFS) and overall survival (OS) between the two groups was performed using Log-rank test. Results show that patients with higher CTC numbers exhibited a significantly shorter PFS and OS compared to those in the CTC-Low group after the 8th NCT course (Fig. 6D and 6E). In addition, we evaluated the survival of patients with High-R and Low-R (according to the Ki-67 index) and found patients in the High-R group had significantly higher PFS and OS than patients in the Low-R group (Additional file 5, Fig S5), which confirms the high reliability of the grouping methods.

Discussion

Liquid biopsy is the focus of precision oncology as it is noninvasive and can be repeated at multiple time points, facilitating the monitoring of disease courses and therapy selection[20]. However, the predictive value of CTCs for NCT response remains controversial. CTC detection clinical trials based on the CellSearch® system suggested EpCAM-positive CTC counts were not correlated to pCR in NCT[21, 22]. Our previous study demonstrated that systemic adjuvant chemotherapy had a significant impact on CTCs, as assessed via RT-PCR, and this effect was observed after three cycles of chemotherapy[7]. The data also indicated the decline of CTC positive rates in NCT, which emboldened the rationale for use of CTCs as a biomarker in NCT response monitoring[23]. These inconsistent results may be due to the use of different detection platforms. Mego and colleagues measured CTC by CellSearch® or AdnaTest™ and their results demonstrated that epithelial-mesenchymal transition (EMT) phenotype CTCs may occur in the peripheral circulation of patients, and NCT is unable to eliminate CTCs undergoing EMT[24].

In the present study, the SE-i-FISH® platform was used for CTC detection and characterization. Recently, this method has been validated for detection of various rare tumor cells including CTCs and cerebrospinal tumors[25–28]. SE-i-FISH® effectively isolates CTCs without hypotonic damage and detects different CTC subtypes regardless of size variation and epithelial or mesenchymal phenotypes. In this study, the positive CTC rate is similar to the results presented by Camara and colleague[29], yet higher than those reported by other researchers[30, 31]. Several factors may account for this discrepancy. First, our results proved Fisher's theory that hematogenous metastasis could be found in early phase breast cancer, as it is a systematic disease[32, 33]. The patients enrolled in this study were diagnosed at the locally advanced stage, making the presence of CTCs extremely likely. Secondly, the SE-i-FISH® platform detected CTCs by various tumor markers and chromosome karyotype, which should improve the overall detection rate. The high sensitivity of this technique has been verified in other malignancies including cancers of the liver, lung, colorectum, and kidneys[25, 28].

One of the most remarkable results of our study was an observed obvious increase in CTC numbers (both total and subtype) after the first course of NCT that was maintained at a high level until surgery. A similar elevation following the first course of NCT has been reported in a previous study, although different CTC capture rates existed due to the different testing methods; researchers found that CTC numbers increased concomitantly with taxane-induced tumor size-reduction[29]. More focus is placed on the changes between the baseline and post-NCT CTC numbers. A meta-analysis suggested that CTC counts decreased after NCT compared to the baseline[4]. However, this study used the CellSearch® System as the only detection method, and chemotherapy may have a substantial impact on epithelial and mesenchymal phenotypes. Hence, there were considerable differences between our SE-i-FISH® platform-based results and previous studies.

Changes in proliferation are a prerequisite for changes in tumor growth rate and a decrease in the Ki-67 proliferation index during NCT is predictive of long-term benefits[34, 35]. A large reduction in Ki-67 indicates that NCT may be effective. Alternatively, a small reduction, unchanged, or increased Ki-67 indicate that NCT may be ineffective. Some researchers have argued that although a tumor may exhibit a large initial decrease in the Ki-67 index, if it remains high after NCT there remains a high risk of recurrence[36]. Unlike the prognostic model in our earlier study, the chemotherapy response prediction model was applied in the present study. Ki-67 index fluctuation is the best group standard test to distinguish different tumor cell sensitivities to chemotherapy.

The Miller-Payne system was constructed in 2003[17], and was generally accepted by oncologists. It was applied to patient groupings in this study to analyze the correlation between CTCs and clinical response. Herein, eight patients were classified as Miller-Payne grade 4 or 5 after NCT, all of whom had a high Ki-67 index reduction. By this standard, the trend in variation was the same as the Ki-67 grouping (data presented in supplementary material). However, due to the extremely uneven sample numbers (8 vs 37), further assessment is required with a larger survey sample.

The comparison of CTC numbers at different time points based on chemotherapy response grouping is of high clinical value. As treatment progresses, the difference between CTC levels in High-R and Low-R groups increased. The continuous rise of CTC numbers in the Low-R group was the most notable trend. The general upward trend of CTC numbers with time may be attributed to the increase in the Low-R group in this study.

Spontaneous chromosome mis-segregation events in aneuploid cells promote chromosomal instability (CIN) that can give rise to intrinsic multidrug resistance compared to CIN- cell lines[37]. Several studies have demonstrated a correlation between Chr8 ploidy in CTCs and chemotherapy resistance in different tumors[27, 38–40]. In advanced gastric cancer, triploid Chr8 CTCs exhibited intrinsic drug resistance, whereas tetra- and multiploid CTCs may develop acquired resistance following chemotherapy[38]. The drug resistance character of triploid Chr8 CTCs was also observed in nasopharyngeal carcinoma[27] and locally advanced rectal cancer. To our knowledge, this study analyzed the quantity and proportion of Chr8 aneuploidy in NCT at different time points grouped by chemotherapy response for the first time in patients with LABC. During NCT, the number of triploid and tetraploid Chr8 CTCs increased only in the Low-R group. More importantly, an increasing proportion with time was found in the Low-R group.

Traditional methods marked by the CellSearch® System and RT-PCR are incapable of identifying CTC size. Complementary techniques such as ISET (isolation by size of epithelial tumor cells), based on a direct size selection method for epithelial cell enrichment to further filter small CTCs may be applied to generate additional information. Research has shown the number of small CTCs is increased following chemotherapy and is accompanied by the increased ratio of drug-resistant to drug-sensitive CTCs[41]. CTMs, derived from oligoclonal groups of cells from the primary tumor, have a 23- to 50-fold increased metastatic potential compared to single CTCs[42]. In the present study, both small size CTCs and CTMs were detected; an increase in small CTCs over the course of chemotherapy was found. We attribute the overall increase of small CTC number to the increase seen in the Low-R patients. In contrast, no significant changes in CTM number occurred during NCT, indicating that CTM may have a closer relationship with metastasis than drug resistance.

Some studies have indicated that CTCs with an EMT phenotype may occur in the peripheral circulation of patients with breast cancer[24]. Patients with vimentin + CTCs had worse survival rates than those with CK + CTCs[43]. In this study, results show the close relationship between vimentin- CTC numbers (large and small CTCs) and low therapy response. The proportion of vimentin- CTCs and small CTCs increased throughout the Low-R group. Notably, an increase then decrease of mesenchymal CTCs was found during NCT, especially in large CTCs of the High-R group. There is no clear explanation for this phenomenon to date. Chemotherapy could promote the EMT of primary tumor cells by multiple pathways[44, 45] resulting in the initial increase. A study has

provided evidence that EMT tumor cells modulate NK cell ligands and are vulnerable to NK-mediated cytotoxicity[46]; activation of the innate immune system may result in decreasing numbers over time.

Positive correlations between CTCs and blood cells (neutrophils and platelets) were also observed before NCT. During the metastatic process, cancer cells encounter many other circulating cells. Several studies have shown that circulating platelets and neutrophils contribute to the binding of cancer cells to the endothelium and to their extravasation across the endothelial barrier[47–49]. However, throughout the course of NCT, this correlation disappeared due to the myelosuppression caused by chemotherapy.

The diagnostic efficacy of CTCs in distinguishing different chemotherapeutic responses was tested in this study. Effective performance correlations were demonstrated for almost all indicators described based upon determinations made before surgery. However, if predicting the NCT response based only on the CTC number post-first course, the only relatively accurate indicator was the Δ value1 of vimentin- small size CTCs. The well-known SWOG S0500 clinical trial demonstrated that for patients with persistently increased CTCs after 21 days of first-line chemotherapy, early switching to an alternative cytotoxic therapy was ineffective in prolonging overall survival[50]. Our study also found low diagnostic performance after one course of chemotherapy. However, it is expected that testing over a longer timeframe will result in higher forecasting performance with this new CTC detection platform.

Although surrogate endpoints including the Ki-67 and Miller-Payne system are commonly accepted, it is widely accepted that these methods carry with them a certain level of inherent risk. Therefore, in the present study, our follow-up outcome was used to evaluate the grouping methods and to overcome the skepticism. Patients with High-R showed lower recurrence than those in the Low-R. More importantly, we observed specific significant differences between PFS and OS and patients with different levels of CTCs. Cumulatively, these results confirm that CTC numbers could be used as an evaluation index for the prognosis of LABC.

Conclusions

During a typical NCT course specific CTC subtypes in peripheral blood may allow for rapid evaluation of NCT response. Detection at additional time points may increase the predictive capacity of CTCs to improve unfavorable outcome rates in LABC patients.

Abbreviations

LABC: locally advanced breast cancer; NCT: neoadjuvant chemotherapy; CTC: circulating tumor cells; SE-i-FISH: subtraction enrichment and immunostaining fluorescence *in situ* hybridization; PFS: progression-free survival; OS: overall survival; ROC: Receiver operating characteristic; AUC: the area under the ROC curve.

Declarations

Ethics approval and consent to participate

Samples were collected at the First Affiliated Hospital with Nanjing Medical University. Ethics approval was obtained from the institutional ethics committee of the First Affiliated Hospital with Nanjing Medical University and written informed consent was obtained from all participants.

Consent for publication

All authors have given consent for publication.

Availability of data and materials

All remaining data and materials are available from the authors upon reasonable request.

Competing interests

The authors declared no potential conflicts of interest.

Funding

This study was funded by the Natural Science Foundation of China (81572607 and 81572602).

Author Contributions:

Ge Ma: conceptualization, project administration, formal analysis, writing – original draft, and writing – review and editing. Jingyi Wang: project administration and data analysis. Xingmeng Wang: data curation and methodology. Hanling Zeng: project administration and data processing. Minghui Li: writing – original draft and writing – review and editing. Xu Han: data analysis. Xinrui Mao: data analysis. Yi Jiang: data curation. Tiansong Xia: conceptualization and project administration. Xiaolan Liu: conceptualization and funding acquisition. Shui Wang: conceptualization, supervision and funding acquisition

Acknowledgements

The authors wish to thank all the patients and family members for participating in this study.

Authors details

1. Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, 210029, Nanjing, China;
2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center For Cancer Personalized Medicine, School of Pub
3. Department of General Surgery, The First People's Hospital of Yancheng City, Yancheng, China.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: **Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.** *CA: a cancer journal for clinicians* 2018, **68**(6):394-424.
2. Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM: **Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy.** *Cancer research* 2008, **68**(2):516-520.
3. Comen E, Norton L, Massague J: **Clinical implications of cancer self-seeding.** *Nature reviews Clinical oncology* 2011, **8**(6):369-377.
4. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S *et al*: **Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.** *Journal of the National Cancer Institute* 2018, **110**(6):560-567.
5. Caixeiro NJ, Kienzle N, Lim SH, Spring KJ, Tognela A, Scott KF, de Souza P, Becker TM: **Circulating tumour cells—a bona fide cause of metastatic cancer.** *Cancer metastasis reviews* 2014, **33**(2-3):747-756.
6. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B: **The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients.** *Breast cancer research : BCR* 2011, **13**(3):R61.
7. Chong MH, Zhao Y, Wang J, Zha XM, Liu XA, Ling LJ, Du Q, Wang S: **The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform.** *British journal of cancer* 2012, **106**(10):1605-1610.
8. van Dalum G, van der Stam GJ, Tibbe AG, Franken B, Mastboom WJ, Vermes I, de Groot MR, Terstappen LW: **Circulating tumor cells before and during follow-up after breast cancer surgery.** *International journal of oncology* 2015, **46**(1):407-413.
9. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S *et al*: **Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.** *Cancer* 2010, **116**(14):3330-3337.
10. Nole F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N *et al*: **Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications.** *Annals of oncology : official journal of the European Society for Medical Oncology* 2008, **19**(5):891-897.
11. Riethdorf S, Muller V, Loibl S, Nekljudova V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F *et al*: **Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial.** *Clinical cancer research : an official journal of the American Association for Cancer Research* 2017, **23**(18):5384-5393.
12. Andergassen U, Kolbl AC, Mahner S, Jeschke U: **Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review).** *Oncology reports* 2016, **35**(4):1905-1915.
13. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J *et al*: **Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.** *Science translational medicine* 2013, **5**(179):179ra147.
14. Passerini V, Ozeri-Galai E, de Pagter MS, Donnelly N, Schmalbrock S, Kloosterman WP, Kerem B, Storchova Z: **The presence of extra chromosomes leads to genomic instability.** *Nature communications* 2016, **7**:10754.
15. Gordon DJ, Resio B, Pellman D: **Causes and consequences of aneuploidy in cancer.** *Nature reviews Genetics* 2012, **13**(3):189-203.
16. Kops GJ, Weaver BA, Cleveland DW: **On the road to cancer: aneuploidy and the mitotic checkpoint.** *Nature reviews Cancer* 2005, **5**(10):773-785.
17. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD: **A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.** *Breast (Edinburgh, Scotland)* 2003, **12**(5):320-327.
18. Lin PP: **Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells.** *Clinical and translational medicine* 2015, **4**(1):38.
19. Lin PP, Gires O, Wang DD, Li L, Wang H: **Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells.** *Scientific reports* 2017, **7**(1):9789.
20. Heitzer E, Haque IS, Roberts CES, Speicher MR: **Current and future perspectives of liquid biopsies in genomics-driven oncology.** *Nature reviews Genetics* 2019, **20**(2):71-88.
21. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A, Marty M: **Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.** *Clinical cancer research : an official journal of the American Association for Cancer Research* 2008, **14**(21):7004-7010.

22. Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB *et al*: **Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.** *Molecular cancer therapeutics* 2015, **14**(3):821-827.
23. Kasimir-Bauer S, Bittner AK, Konig L, Reiter K, Keller T, Kimmig R, Hoffmann O: **Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.** *Breast cancer research : BCR* 2016, **18**(1):20.
24. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN *et al*: **Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.** *International journal of cancer* 2012, **130**(4):808-816.
25. Li X, Zhang Y, Ding J, Wang M, Li N, Yang H, Wang K, Wang D, Lin PP, Li M *et al*: **Clinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis.** *Oncotarget* 2018, **9**(2):2705-2714.
26. Li Y, Zhang X, Gong J, Zhang Q, Gao J, Cao Y, Wang DD, Lin PP, Shen L: **Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer.** *Chinese journal of cancer research = Chung-kuo yen cheng yen chiu* 2016, **28**(6):579-588.
27. Zhang J, Shi H, Jiang T, Liu Z, Lin PP, Chen N: **Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma.** *BMC cancer* 2018, **18**(1):1133.
28. Ye Z, Ding Y, Chen Z, Li Z, Ma S, Xu Z, Cheng L, Wang X, Zhang X, Ding N *et al*: **Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies.** *Cancer biology & therapy* 2018:1-6.
29. Camara O, Rengsberger M, Egbe A, Koch A, Gajda M, Hammer U, Jorke C, Rabenstein C, Untch M, Pachmann K: **The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.** *Annals of oncology : official journal of the European Society for Medical Oncology* 2007, **18**(9):1484-1492.
30. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulas V *et al*: **Prognostic value of the molecular detection of circulating tumor cells using a multimer reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research* 2008, **14**(9):2593-2600.
31. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jorke C, Hammer U, Altendorf-Hofmann A *et al*: **Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008, **26**(8):1208-1215.
32. Fisher B, Fisher ER: **The organ distribution of disseminated 51 Cr-labeled tumor cells.** *Cancer research* 1967, **27**(2):412-420.
33. Fisher B, Fisher ER, Feduska N: **Trauma and the localization of tumor cells.** *Cancer* 1967, **20**(1):23-30.
34. Miglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, Parodi MA, Morabito F: **Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.** *Oncology* 2010, **79**(3-4):255-261.
35. Li L, Han D, Wang X, Wang Q, Tian J, Yao J, Yuan L, Qian K, Zou Q, Yi W *et al*: **Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis.** *Future oncology (London, England)* 2017, **13**(11):1021-1034.
36. Miglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M: **A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.** *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology* 2013, **39**(10):1046-1052.
37. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M *et al*: **Chromosomal instability confers intrinsic multidrug resistance.** *Cancer research* 2011, **71**(5):1858-1870.
38. Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, Zhang Q, Cao Y, Wang DD, Lin PP *et al*: **Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer.** *Oncotarget* 2014, **5**(16):6594-6602.
39. Wan JF, Li XQ, Zhang J, Yang LF, Zhu J, Li GC, Liang LP, Shen LJ, Zhang H, Li J *et al*: **Aneuploidy of chromosome 8 and mutation of circulating tumor cells predict pathologic complete response in the treatment of locally advanced rectal cancer.** *Oncology letters* 2018, **16**(2):1863-1868.
40. Li Y, Zhang X, Liu D, Gong J, Wang DD, Li S, Peng Z, Li Y, Wang X, Lin PP *et al*: **Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance.** *Clinical cancer research : an official journal of the American Association for Cancer Research* 2018, **24**(21):5261-5271.
41. Ito H, Yamaguchi N, Onimaru M, Kimura S, Ohmori T, Ishikawa F, Sato J, Ito S, Inoue H: **Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer.** *Oncology letters* 2016, **12**(6):4720-4726.
42. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H *et al*: **Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.** *Cell* 2014, **158**(5):1110-1122.
43. Zhang D, Zhao L, Zhou P, Ma H, Huang F, Jin M, Dai X, Zheng X, Huang S, Zhang T: **Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy.** *Cancer cell international* 2017, **17**:6.
44. Ma G, Huang H, Li M, Li L, Kong P, Zhu Y, Xia T, Wang S: **Plasma CCL5 promotes EMT-mediated epirubicin-resistance in locally advanced breast cancer.** *Cancer biomarkers : section A of Disease markers* 2018, **22**(3):405-415.
45. Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, Wang WJ, Chen Q, Tang F, Liu XP *et al*: **Involvement of NF-kappaB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.** *Cell death and differentiation* 2011, **18**(1):16-25.
46. Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG: **Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.** *The Journal of clinical investigation* 2018, **128**(4):1384-1396.

47. Somasundaram R, Herlyn D: **Chemokines and the microenvironment in neuroectodermal tumor-host interaction**. *Seminars in cancer biology* 2009, **19**(2):92-96.
48. Coupland LA, Chong BH, Parish CR: **Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells**. *Cancer research* 2012, **72**(18):4662-4671.
49. Reymond N, d'Agua BB, Ridley AJ: **Crossing the endothelial barrier during metastasis**. *Nature reviews Cancer* 2013, **13**(12):858-870.
50. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL *et al*: **Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500**. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2014, **32**(31):3483-3489.

Additional Files

Additional file 1:

Figure S1: Correlation of CTCs and lymph nodes metastasis.

1. A) CTC numbers increased in the patients with more than two lymph node metastases. A significantly higher number of CTCs was observed in patients with advanced tumors after the first course of NCT. B and C) A subgroup analysis of the correlation between CTC numbers and treatment response in patients with different tumor stages. For all patients in the Low-R group, CTC number increased continually. In the High-R group, the change in CTC number had an increase-then-decrease trend in the 0-2 metastatic lymph node subgroup. In the subgroup with more than two metastatic lymph nodes, the CTC number remained steady throughout NCT.

Additional file 2:

Figure S2: Correlation between CTCs and other circulating cells. Correlation between CTC and lymphocyte, neutrophils and platelets at three time points.

Additional file 3:

Figure S3: The correlation between CTCs and the tumor markers CEA, CA12-5, and CA15-3.

Additional file 4:

Figure S4: ROC curve grouped by the Miller-Payne system.

A: Number and subtypes of CTCs after the eighth course of NCT.

B: Δ value2 (the difference between the third and the first timepoints) of total CTCs and CTC subtypes.

Additional file 5:

Figure S5: PFS and OS analysis for patients in High-R and Low-R groups (Ki-67 index mode).

Figures




Figure 1
Detection of CTCs by SE-iFISH. A) A CTC with EpCAM+ vimentin- \geq pentasomy 8. B) A small CTC with EpCAM- vimentin+ disomy 8. C) A CTM with EpCAM+ vimentin- by SE-iFISH. (WBC: red arrow).




Figure 2
CTC levels in patients during NCT. A) A typical fluorescent photograph of a CTC and three WBCs (red arrows). B) Trend in total CTCs during treatment. Measurements after the eighth course of treatment revealed more CTCs in patients receiving NCT. C) The difference in CTC numbers between the two response groups at three time points (Ki-67 index mode). There was no significant difference in number of CTCs until the first course of NCT. Low-R patients

had higher levels of CTC than High-R patients before surgery. D) The CTC number increased slightly ($p = 0.051$) but then returned to baseline in the High-R group; in contrast, the number increased continuously during NCT in the Low-R group (Ki-67 index mode). E) The difference in CTC numbers between Miller-Payne grades 1-3, and 4-5 at three time points. There was no significant difference in CTC number until the first course NCT. Miller-Payne grade 1-3 patients had higher levels of CTCs than Miller-Payne grade 4-5 patients before surgery. F) No significant changes in CTC number were detected in the Miller-Payne 4-5 group during NCT; in contrast, the CTC number increased continuously during NCT in the grade 1-3 group.




Figure 3

Changes in CTC numbers and proportion with different chromosome 8 karyotypes between patients with different responses to NCT. A) Images of CTCs with different chromosome 8 ploidies. CTC nuclei were stained with DAPI (blue) and chromosome 8 was imaged with centromere probe 8 spectrum orange (red dots). B) Quantitative composition of CTC subtypes with different chromosome 8 ploidies in entire populations of CTCs detected in High-R and Low-R groups at three time points. C) Comparison of trisomy 8 CTCs between the two response groups (Ki-67 index mode). No significant differences were observed between High-R and Low-R patients at the first two time points. The trisomy 8 CTC number increased in the Low-R group after the eighth course. D) Comparison of trisomy 8 CTC subtypes over the course of NCT (Ki-67 index mode). Compared to the CTC number before NCT, the triploid chromosome 8 CTCs increased in the Low-R group post-first NCT and post-NCT. Triploid chromosome 8 increased post-first NCT and returned to baseline level in the High-R group post-eighth NCT. E) Comparison of trisomy 8 CTCs between the two response groups. No significant differences were observed between Miller-Payne grade 4-5 and 1-3 patients at the first two time points. The trisomy 8 CTC number increased in the Miller-Payne grade 1-3 group after the eighth course. F) Compared to the CTC number before NCT, triploid chromosome 8 CTCs increased in Miller-Payne grade 1-3 patients post-first NCT and post-NCT. G) Comparison of tetrasomy 8 CTCs between the two response groups (Ki-67 index mode). The tetrasomy 8 CTC number was higher in the Low-R group than the High-R group after the eighth course. There was no difference between these two groups previously. H) Comparison of tetrasomy 8 CTC subtypes over the course of NCT (Ki-67 index mode). No increase of tetraploid chromosome 8 was observed in CTCs over the course of NCT in High-R patients. The number of CTCs with tetrasomy 8 increased significantly until the last detection in Low-R patients. I) Comparison of tetrasomy 8 CTCs between the two groups. The tetrasomy 8 CTC number was higher in the Miller-Payne grade 1-3 group than the Miller-Payne grade 4-5 group after the eighth NCT course. There was no difference between these two groups previously. J) No increase in tetraploid chromosome 8 was observed in CTCs over the course of NCT in Miller-Payne grade 4-5 patients. The number of CTCs with tetrasomy 8 increased significantly until the last detection in the Miller-Payne grade 1-3 group. K) There were no significant differences between the Low-R and High-R groups during NCT in numbers of multiploid (\geq pentasomy 8) CTCs for either of the post-NCT time points (Ki-67 index mode). L) No significant differences in multiploid (\geq pentasomy 8) CTCs within groups were detected in High-R patients and the number of multiploid (\geq pentasomy 8) CTCs increased after the first course of NCT (Ki-67 index mode). M) There were no significant differences between Miller-Payne grades 1-3,

and 4-5 at three time points during NCT in numbers of multiploid (\geq pentasomy 8) CTCs for either of the post-NCT time points. N) No significant differences in multiploid (\geq pentasomy 8) CTCs within groups were detected in Miller-Payne grades 4-5 patients and the number of multiploid (\geq pentasomy 8) CTCs increased after the first course of NCT in patients of Miller-Payne grades 1-3.




Figure 4
 Correlation of small size CTCs, CTM and chemotherapeutic effect. A) Left, photograph of a small size CTC; Right, image of a two CTC cluster microembolus. B) Quantitative comparison of small CTCs. The number of small size CTCs continued to increase during NCT. C) Compared to the High-R group (Ki-67 index mode), the number of small CTCs in the Low-R group increased significantly after the eighth course of NCT. D) The number of small CTCs in Low-R patients rose after the first course of NCT and then remained constant at a comparatively high level. The CTC level of High-R patients remained approximately constant during NCT (Ki-67 index mode). E) Compared to the Miller-Payne grade 4-5 group, the number of small CTCs in the Miller-Payne grade 1-3 group increased significantly after the eighth course of NCT. F) The number of small CTCs in Miller-Payne grade 1-3 patients rose after the first course of NCT, then remained constant at a comparatively high level. G) Overall proportion changes and changes within response groups. The proportion of small CTCs increased during NCT. The proportion of small CTC in High-R patients rose from 30.5% to 35.9%, the change in the Low-R was from 14.5% to 46.7%. H) No significant change in CTM numbers was found for the different patient groups following NCT. I) Post-first course samples showed significantly higher CTM numbers in Low-R patients compared to pre-NCT samples. CTM numbers in the High-R group remained approximately constant during NCT.




Figure 5

CTCs with different mesenchymal phenotype exhibited different sensitivities to NCT. A) Images of CTCs and small size cell CTCs with vimentin+. B and C) Number of total CTCs and small CTCs with vimentin- increased during NCT. Total vimentin+ CTCs increased after the first course and decreased after the last course. Small vimentin+ CTCs increased after the first course and then remained constant. D and F) No differences were found in vimentin+ total CTC occurrence between the two response groups. However, more vimentin+ small CTCs were detected in the High-R group after the first course of NCT. E) The number of total vimentin+ CTCs did not change during NCT. G) The vimentin+ CTC number increased post-first NCT and returned to baseline level in the High-R group. No significant changes in number were detected in the Low-R group during NCT. H and J) Patients in the Low-R group displayed higher numbers of vimentin- CTCs and small CTCs after NCT than the High-R group. I) Vimentin- CTCs remained constant in the High-R group, but in the Low-R group, increased after the first course of NCT and remained at the same high level until surgery. K) Small vimentin- CTCs showed no change in the High-R group but increased after the first course of NCT and remained at the same high level in Low-R group. L) The proportion of small CTCs with different mesenchymal phenotypes. In the Low-R group, the percentage of vimentin- small CTCs rose from 10% before NCT to 47% after all courses.




Figure 6 Receiver operating characteristic (ROC) curves for CTC numbers with different subtypes for discriminating low response from high-response and prognostic value of the CTC numbers for LABC patients. AUC: area under the curve. A) Number of CTCs and subtypes of CTC after the eighth course of NCT. B) Δ value2 (difference between the third and the first timepoints) of CTCs and CTC subtypes. C) The Δ value1 (difference between the second and the first timepoints) of vimentin+ small size CTCs. D) Progression-free survival analysis for LABC patients receiving NCT. E) Overall survival analysis for LABC patients receiving NCT.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigS3.tif](#)
- [FigS5.jpg](#)
- [FigS1.tif](#)
- [FigS2.jpg](#)
- [FigS4.jpg](#)